Aneta Lidia Zygulska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aneta Lidia Zygulska has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Krzysztof Krzemieniecki
Department of Oncology, University Hospital in Cracow, Cracow, Poland
6 shared publicationsA. Furgala
Jagiellonian Univ Med Coll, Dept Pathophysiol, Krakow, Poland
2 shared publications- Agata Furgała
Department of Pathophysiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
2 shared publications Anna Sowa-Staszczak
2 shared publicationsBeata Wlodarczyk
Department of Pathophysiology, Jagiellonian University Medical College, Cracow, Poland
2 shared publicationsK. Krzemieniecki
Krakow Univ Hosp, Dept Oncol, 2 Jakubowskiego St, PL-30688 Krakow, Poland
2 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (8) , 1281-1295
Oxaliplatin-induced peripheral neuropathy in cancer treatment: Mechanisms, risk factors, and management strategies
Oxaliplatin (OXI) is a platinum-based chemotherapeutic agent commonly used in the systemic treatment of colorectal, gastric, pancreatic, and esophageal cancers. Like other cytotoxic agents, OXI is associated with various adverse effects; however, OXI-induced peripheral neuropathy (OIPN) represents a particularly challenging clinical problem for both oncologic patients and their clinicians. The severity of neuropathic symptoms may necessitate dose reduction or premature discontinuation of therapy, which can ultimately shorten recurrence-free survival. This paper discusses the symptoms, mechanisms of onset, risk factors, preventive strategies, treatment options, and grading scales associated with OIPN. Both the prevention and treatment of OIPN require further innovative and effective research. It is hoped that the outcomes of ongoing trials will address both chronic and acute OIPN in the near future, as this condition remains a persistent clinical concern for patients with gastrointestinal cancers.
- 2 April 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (8) , 1281-1295
Open AccessOxaliplatin-induced peripheral neuropathy in cancer treatment: Mechanisms, risk factors, and management strategies
Oxaliplatin (OXI) is a platinum-based chemotherapeutic agent commonly used in the systemic treatment of colorectal, gastric, pancreatic, and esophageal cancers. Like other cytotoxic agents, OXI is associated with various adverse effects; however, OXI-induced peripheral neuropathy (OIPN) represents a particularly challenging clinical problem for both oncologic patients and their clinicians. The severity of neuropathic symptoms may necessitate dose reduction or premature discontinuation of therapy, which can ultimately shorten recurrence-free survival. This paper discusses the symptoms, mechanisms of onset, risk factors, preventive strategies, treatment options, and grading scales associated with OIPN. Both the prevention and treatment of OIPN require further innovative and effective research. It is hoped that the outcomes of ongoing trials will address both chronic and acute OIPN in the near future, as this condition remains a persistent clinical concern for patients with gastrointestinal cancers.
- 29 July 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (4) , 1577-1579
Non-resective treatment of pineoblastoma in adult: a case report
- 29 July 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (4) , 1577-1579
Non-resective treatment of pineoblastoma in adult: a case report
- Top Cited PapersOpen Access
- 13 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 852
Novel Diagnostic Biomarkers in Colorectal Cancer
Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.
- 13 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 852
Top Cited PapersOpen AccessNovel Diagnostic Biomarkers in Colorectal Cancer
Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.
- 1 January 2021
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 122 (05) , 347-356
The effect of visceral reception activation (water load test) on autonomic activity and gastric myoelectric activity in gastrointestinal malignancies
The effect of visceral reception activation (water load test) on autonomic activity and gastric myoelectric activity in gastrointestinal malignancies
- 1 January 2021
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 122 (05) , 347-356
The effect of visceral reception activation (water load test) on autonomic activity and gastric myoelectric activity in gastrointestinal malignancies
The effect of visceral reception activation (water load test) on autonomic activity and gastric myoelectric activity in gastrointestinal malignancies
- Open Access
- 18 December 2019
- Published by IntechOpen
Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
In this paper, currently available systemic treatment options (regorafenib, trifluridine/tipiracil, re-challenge chemotherapy, mitomycin C plus capecitabine) for pretreated patients with metastatic colorectal cancer are discussed and compared in terms of their efficacy and safety profiles. Treatment of these patients has remained a challenge for oncologists. The evidence from clinical trials is encouraging. Knowledge of response biomarkers and/or prognostic factors may be helpful in the identification of patients who could benefit most from the treatment. Adequate medication compliance can be achieved due to awareness of toxicity risk among both physicians and cancer patients and appropriate prevention and management of adverse events.
- 18 December 2019
- Published by IntechOpen
Open AccessFurther Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
In this paper, currently available systemic treatment options (regorafenib, trifluridine/tipiracil, re-challenge chemotherapy, mitomycin C plus capecitabine) for pretreated patients with metastatic colorectal cancer are discussed and compared in terms of their efficacy and safety profiles. Treatment of these patients has remained a challenge for oncologists. The evidence from clinical trials is encouraging. Knowledge of response biomarkers and/or prognostic factors may be helpful in the identification of patients who could benefit most from the treatment. Adequate medication compliance can be achieved due to awareness of toxicity risk among both physicians and cancer patients and appropriate prevention and management of adverse events.
- 21 November 2018
- Published by Elsevier in Advances in Medical Sciences
- Vol. 64 (1) , 44-53
Association between gastric myoelectric activity disturbances and dyspeptic symptoms in gastrointestinal cancer patients
- 21 November 2018
- Published by Elsevier in Advances in Medical Sciences
- Vol. 64 (1) , 44-53
Association between gastric myoelectric activity disturbances and dyspeptic symptoms in gastrointestinal cancer patients
- 28 May 2018
- Published by Taylor & Francis in Cancer Investigation
- Vol. 36 (5) , 255-263
Autonomic dysregulation in colon cancer patients
To the best of our knowledge, only two studies analyzed the relationship between HRV and carcinoembryonic antigen (CEA) in colon cancer patients. The aim of this study was to analyze changes in the autonomic activity of colon cancer patients using heart rate variability (HRV) and blood pressure variability (BPV) measures, and to verify if HRV and BPV parameters correlate with hemodynamic indices in this group and the plasma levels of CEA. Presence of colon cancer is associated with changes in autonomic activity, namely parasympathetic-sympathetic imbalance in form of sympathetic overdrive. Cancer-related autonomic dysfunction may contribute to impairment of gastrointestinal motility.
- 28 May 2018
- Published by Taylor & Francis in Cancer Investigation
- Vol. 36 (5) , 255-263
Autonomic dysregulation in colon cancer patients
To the best of our knowledge, only two studies analyzed the relationship between HRV and carcinoembryonic antigen (CEA) in colon cancer patients. The aim of this study was to analyze changes in the autonomic activity of colon cancer patients using heart rate variability (HRV) and blood pressure variability (BPV) measures, and to verify if HRV and BPV parameters correlate with hemodynamic indices in this group and the plasma levels of CEA. Presence of colon cancer is associated with changes in autonomic activity, namely parasympathetic-sympathetic imbalance in form of sympathetic overdrive. Cancer-related autonomic dysfunction may contribute to impairment of gastrointestinal motility.
- 1 January 2017
- Published by AEPress, s.r.o. in Neoplasma
- Vol. 64 (03) , 421-429
Enterohormonal disturbances in colorectal cancer patients
Enterohormonal disturbances in colorectal cancer patients
- 1 January 2017
- Published by AEPress, s.r.o. in Neoplasma
- Vol. 64 (03) , 421-429
Enterohormonal disturbances in colorectal cancer patients
Enterohormonal disturbances in colorectal cancer patients
- 1 January 2014
- Vol. 22 (2) , 137-44
Assessment of skin-related toxicity in patients with metastatic colorectal cancer treated with cetuximab.
Monoclonal antibodies (mAbs) blocking the epidermal growth factor receptor (EGFR) pathway, such as cetuximab, have been widely used in recent years for the treatment of metastatic colorectal cancer (mCRC). The purpose of this study was to evaluate the profile of the side effects of cetuximab affecting the skin and its appendages. We gathered the medical records on skin-related toxicity in 46 patients treated with cetuximab for mCRC in the Department of Clinical Oncology, University Hospital in Krakow in 2009-2013. Skin toxicity was classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0. The typical side effects of cetuximab were observed. The most common skin toxicity was an acne-like skin rash (80% of patients) and paronychia (20%). Other side effects were trichomegaly, hypertrichosis, and allergic reactions. In view of high incidence of skin lesions during treatment with cetuximab, it is essential to observe patients carefully and to control the side effects during therapy. Previous experience from clinical trials shows that in some cases proper care and prevention can improve the quality of the patients' lives.
- 1 January 2014
- Vol. 22 (2) , 137-44
Assessment of skin-related toxicity in patients with metastatic colorectal cancer treated with cetuximab.
Monoclonal antibodies (mAbs) blocking the epidermal growth factor receptor (EGFR) pathway, such as cetuximab, have been widely used in recent years for the treatment of metastatic colorectal cancer (mCRC). The purpose of this study was to evaluate the profile of the side effects of cetuximab affecting the skin and its appendages. We gathered the medical records on skin-related toxicity in 46 patients treated with cetuximab for mCRC in the Department of Clinical Oncology, University Hospital in Krakow in 2009-2013. Skin toxicity was classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0. The typical side effects of cetuximab were observed. The most common skin toxicity was an acne-like skin rash (80% of patients) and paronychia (20%). Other side effects were trichomegaly, hypertrichosis, and allergic reactions. In view of high incidence of skin lesions during treatment with cetuximab, it is essential to observe patients carefully and to control the side effects during therapy. Previous experience from clinical trials shows that in some cases proper care and prevention can improve the quality of the patients' lives.